{"id": "IEPA.d0.s0_IEPA.d0.s0.p0", "text": "Oxytocin stimulates IP3 production in dose-dependent fashion as well", "text_with_entity_marker": "[E1]Oxytocin[/E1] stimulates [E2]IP3[/E2] production in dose-dependent fashion as well", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Oxytocin", "entity_1_idx": [[0, 8]], "entity_1_idx_in_text_with_entity_marker": [4, 12], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "IP3", "entity_2_idx": [[20, 23]], "entity_2_idx_in_text_with_entity_marker": [33, 36], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d2.s3_IEPA.d2.s3.p1", "text": "These results indicate that oTP-1 may prevent luteolysis by inhibiting development of endometrial responsiveness to oxytocin and, therefore, reduce oxytocin-induced synthesis of IP3 and PGF2 alpha", "text_with_entity_marker": "These results indicate that oTP-1 may prevent luteolysis by inhibiting development of endometrial responsiveness to [E1]oxytocin[/E1] and, therefore, reduce oxytocin-induced synthesis of [E2]IP3[/E2] and PGF2 alpha", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "oxytocin", "entity_1_idx": [[116, 124]], "entity_1_idx_in_text_with_entity_marker": [120, 128], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "IP3", "entity_2_idx": [[178, 181]], "entity_2_idx_in_text_with_entity_marker": [191, 194], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d4.s5_IEPA.d4.s5.p0", "text": "The effects of prostaglandin F2 alpha (PGF2 alpha) on intracellular Ca2+ concentration ([Ca2+]i) and inositol phosphate (IP) generation in human myometrial cells were evaluated and compared to the effects of oxytocin", "text_with_entity_marker": "The effects of prostaglandin F2 alpha (PGF2 alpha) on intracellular Ca2+ concentration ([Ca2+]i) and [E1]inositol phosphate[/E1] (IP) generation in human myometrial cells were evaluated and compared to the effects of [E2]oxytocin[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "inositol phosphate", "entity_1_idx": [[101, 119]], "entity_1_idx_in_text_with_entity_marker": [105, 123], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "oxytocin", "entity_2_idx": [[208, 216]], "entity_2_idx_in_text_with_entity_marker": [221, 229], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d8.s16_IEPA.d8.s16.p0", "text": "Endothelin-1 and oxytocin stimulated inositol phosphate accumulation at concentrations similar to those that promoted 45Ca2+ efflux, whereas about 100 times higher concentrations of PGF2 alpha were needed to activate this signaling pathway in intact cells", "text_with_entity_marker": "Endothelin-1 and [E1]oxytocin[/E1] stimulated [E2]inositol phosphate[/E2] accumulation at concentrations similar to those that promoted 45Ca2+ efflux, whereas about 100 times higher concentrations of PGF2 alpha were needed to activate this signaling pathway in intact cells", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "oxytocin", "entity_1_idx": [[17, 25]], "entity_1_idx_in_text_with_entity_marker": [21, 29], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "inositol phosphate", "entity_2_idx": [[37, 55]], "entity_2_idx_in_text_with_entity_marker": [50, 68], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d10.s22_IEPA.d10.s22.p0", "text": "Amyloid beta protein disruption of cholinergic and growth factor phospholipase C signals could underlie cognitive and neurodegerative aspects of Alzheimer's disease", "text_with_entity_marker": "[E1]Amyloid[/E1] beta protein disruption of cholinergic and growth factor [E2]phospholipase C[/E2] signals could underlie cognitive and neurodegerative aspects of Alzheimer's disease", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Amyloid", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "phospholipase C", "entity_2_idx": [[65, 80]], "entity_2_idx_in_text_with_entity_marker": [78, 93], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d11.s28_IEPA.d11.s28.p1", "text": "The phospholipase C inhibitor U 71322 prevented the activation of phospholipase C by A beta P", "text_with_entity_marker": "The [E1]phospholipase C[/E1] inhibitor U 71322 prevented the activation of phospholipase C by [E2]A beta P[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "phospholipase C", "entity_1_idx": [[4, 19]], "entity_1_idx_in_text_with_entity_marker": [8, 23], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "A beta P", "entity_2_idx": [[85, 93]], "entity_2_idx_in_text_with_entity_marker": [98, 106], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d17.s34_IEPA.d17.s34.p2", "text": "The aim of this study was to investigate the effects of hCG, hCG plus oxytocin and oxytocin on [3H] inositol phosphate (IP) formations in porcine myometrial cells obtained from ovariectomized and cyclic gilts", "text_with_entity_marker": "The aim of this study was to investigate the effects of hCG, hCG plus oxytocin and [E1]oxytocin[/E1] on [3H] [E2]inositol phosphate[/E2] (IP) formations in porcine myometrial cells obtained from ovariectomized and cyclic gilts", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "oxytocin", "entity_1_idx": [[83, 91]], "entity_1_idx_in_text_with_entity_marker": [87, 95], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "inositol phosphate", "entity_2_idx": [[100, 118]], "entity_2_idx_in_text_with_entity_marker": [113, 131], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d17.s36_IEPA.d17.s36.p0", "text": "There was also a very significant increase of IP1 after the addition of 1000 mU hCG (p < 0.001) and IP1 and IP3 when 1000 mU hCG plus oxytocin were added (p < 0.001 and p < 0.01, respectively)", "text_with_entity_marker": "There was also a very significant increase of [E1]IP1[/E1] after the addition of 1000 mU hCG (p < 0.001) and [E2]IP1[/E2] and IP3 when 1000 mU hCG plus oxytocin were added (p < 0.001 and p < 0.01, respectively)", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IP1", "entity_1_idx": [[46, 49]], "entity_1_idx_in_text_with_entity_marker": [50, 53], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "IP1", "entity_2_idx": [[100, 103]], "entity_2_idx_in_text_with_entity_marker": [113, 116], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d17.s37_IEPA.d17.s37.p0", "text": "Only oxytocin alone increased the formation of IPs in cells from ovariectomized pigs treated with estradiol in vivo (p < 0.01)", "text_with_entity_marker": "Only [E1]oxytocin[/E1] alone increased the formation of [E2]IPs[/E2] in cells from ovariectomized pigs treated with estradiol in vivo (p < 0.01)", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "oxytocin", "entity_1_idx": [[5, 13]], "entity_1_idx_in_text_with_entity_marker": [9, 17], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "IPs", "entity_2_idx": [[47, 50]], "entity_2_idx_in_text_with_entity_marker": [60, 63], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d21.s45_IEPA.d21.s45.p0", "text": "These data suggest that cAMP-dependent phosphorylation at a step involving GTP-binding protein/PLC coupling can exert a negative effect on the stimulation of IP3 formation by oxytocin and thereby affect contraction/relaxation in the myometrium", "text_with_entity_marker": "These data suggest that cAMP-dependent phosphorylation at a step involving GTP-binding protein/PLC coupling can exert a negative effect on the stimulation of [E1]IP3[/E1] formation by [E2]oxytocin[/E2] and thereby affect contraction/relaxation in the myometrium", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IP3", "entity_1_idx": [[158, 161]], "entity_1_idx_in_text_with_entity_marker": [162, 165], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "oxytocin", "entity_2_idx": [[175, 183]], "entity_2_idx_in_text_with_entity_marker": [188, 196], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d23.s47_IEPA.d23.s47.p2", "text": "The resulting abnormally phosphorylated PrPsc aggregates to freshly synthesized PrPc, transforming it into same; due to a system of positive feedback invoked by the organophosphate-induced blockage of a prion protein-specific protein kinase.", "text_with_entity_marker": "The resulting abnormally phosphorylated [E1]PrPsc[/E1] aggregates to freshly synthesized PrPc, transforming it into same; due to a system of positive feedback invoked by the organophosphate-induced blockage of a prion protein-specific [E2]protein kinase[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PrPsc", "entity_1_idx": [[40, 45]], "entity_1_idx_in_text_with_entity_marker": [44, 49], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "protein kinase", "entity_2_idx": [[226, 240]], "entity_2_idx_in_text_with_entity_marker": [239, 253], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d24.s49_IEPA.d24.s49.p0", "text": "Subcutaneous injections of oxytocin increased insulin, glucagon and glucose levels significantly", "text_with_entity_marker": "Subcutaneous injections of [E1]oxytocin[/E1] increased [E2]insulin[/E2], glucagon and glucose levels significantly", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "oxytocin", "entity_1_idx": [[27, 35]], "entity_1_idx_in_text_with_entity_marker": [31, 39], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[46, 53]], "entity_2_idx_in_text_with_entity_marker": [59, 66], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d24.s51_IEPA.d24.s51.p5", "text": "The oxytocin antagonist 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-oxytocin administered ICV increased insulin levels itself and therefore the effect on oxytocin-induced insulin secretion was difficult to evaluate", "text_with_entity_marker": "The oxytocin antagonist 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-oxytocin administered ICV increased insulin levels itself and therefore the effect on [E1]oxytocin[/E1]-induced [E2]insulin[/E2] secretion was difficult to evaluate", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "oxytocin", "entity_1_idx": [[146, 154]], "entity_1_idx_in_text_with_entity_marker": [150, 158], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[163, 170]], "entity_2_idx_in_text_with_entity_marker": [176, 183], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d32.s68_IEPA.d32.s68.p0", "text": "AVP and OT secretory patterns during insulin (0.15 IU/kg, i.v.)-tolerance tests (ITT) were examined in seven normal male subjects with (experimental tests) and without (control test) concomitant treatment with L-NAME (40 micrograms/kg injected plus 50 micrograms/kg infused, i.v.), the GABAergic agent sodium valproate (600 mg in three divided doses orally) or the combination of L-NAME and sodium valproate", "text_with_entity_marker": "AVP and [E1]OT[/E1] secretory patterns during [E2]insulin[/E2] (0.15 IU/kg, i.v.)-tolerance tests (ITT) were examined in seven normal male subjects with (experimental tests) and without (control test) concomitant treatment with L-NAME (40 micrograms/kg injected plus 50 micrograms/kg infused, i.v.), the GABAergic agent sodium valproate (600 mg in three divided doses orally) or the combination of L-NAME and sodium valproate", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "OT", "entity_1_idx": [[8, 10]], "entity_1_idx_in_text_with_entity_marker": [12, 14], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[37, 44]], "entity_2_idx_in_text_with_entity_marker": [50, 57], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d32.s69_IEPA.d32.s69.p0", "text": "Insulin-induced hypoglycemia increased by 2-fold (peak vs. baseline) plasma AVP and OT levels", "text_with_entity_marker": "[E1]Insulin[/E1]-induced hypoglycemia increased by 2-fold (peak vs. baseline) plasma AVP and [E2]OT[/E2] levels", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Insulin", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "OT", "entity_2_idx": [[84, 86]], "entity_2_idx_in_text_with_entity_marker": [97, 99], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d35.s86_IEPA.d35.s86.p0", "text": "Oxytocin (OT) and vasopressin (AVP) stimulate insulin and glucagon release from the pancreas, and evoke insulin secretion from the rat insulinoma cell line, RINm5F", "text_with_entity_marker": "[E1]Oxytocin[/E1] (OT) and vasopressin (AVP) stimulate [E2]insulin[/E2] and glucagon release from the pancreas, and evoke insulin secretion from the rat insulinoma cell line, RINm5F", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Oxytocin", "entity_1_idx": [[0, 8]], "entity_1_idx_in_text_with_entity_marker": [4, 12], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[46, 53]], "entity_2_idx_in_text_with_entity_marker": [59, 66], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d36.s90_IEPA.d36.s90.p0", "text": "The data provide additional support for the hypothesis that oxytocin and peroxovanadate affect adipose tissue metabolism by mechanisms distinctly different from those involved in insulin action", "text_with_entity_marker": "The data provide additional support for the hypothesis that [E1]oxytocin[/E1] and peroxovanadate affect adipose tissue metabolism by mechanisms distinctly different from those involved in [E2]insulin[/E2] action", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "oxytocin", "entity_1_idx": [[60, 68]], "entity_1_idx_in_text_with_entity_marker": [64, 72], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[179, 186]], "entity_2_idx_in_text_with_entity_marker": [192, 199], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d39.s93_IEPA.d39.s93.p0", "text": "Homogeneous liposome immunoassay for insulin using phospholipase C from Clostridium perfringens", "text_with_entity_marker": "Homogeneous liposome immunoassay for [E1]insulin[/E1] using [E2]phospholipase C[/E2] from Clostridium perfringens", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin", "entity_1_idx": [[37, 44]], "entity_1_idx_in_text_with_entity_marker": [41, 48], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "phospholipase C", "entity_2_idx": [[51, 66]], "entity_2_idx_in_text_with_entity_marker": [64, 79], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d42.s106_IEPA.d42.s106.p0", "text": "Biphasic insulin secretion can be evoked and time-dependent potentiation can be induced in mouse islets by carbachol, an agonist that activates an isozyme of PLC distinct from that activated by glucose", "text_with_entity_marker": "Biphasic [E1]insulin[/E1] secretion can be evoked and time-dependent potentiation can be induced in mouse islets by carbachol, an agonist that activates an isozyme of [E2]PLC[/E2] distinct from that activated by glucose", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "insulin", "entity_1_idx": [[9, 16]], "entity_1_idx_in_text_with_entity_marker": [13, 20], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "PLC", "entity_2_idx": [[158, 161]], "entity_2_idx_in_text_with_entity_marker": [171, 174], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d42.s107_IEPA.d42.s107.p2", "text": "When taken in their entirety, the experimental evidence suggests that the activation of PLC is an essential component in the physiologic regulation of insulin secretion and that disordered activation of the enzyme culminates in disordered insulin release", "text_with_entity_marker": "When taken in their entirety, the experimental evidence suggests that the activation of PLC is an essential component in the physiologic regulation of [E1]insulin[/E1] secretion and that disordered activation of the enzyme culminates in disordered [E2]insulin[/E2] release", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin", "entity_1_idx": [[151, 158]], "entity_1_idx_in_text_with_entity_marker": [155, 162], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[239, 246]], "entity_2_idx_in_text_with_entity_marker": [252, 259], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d47.s122_IEPA.d47.s122.p4", "text": "The maximal insulin responses induced by OT and AVP were very similar, but the threshold and maximal doses of AVP for increasing plasma insulin were higher than those of OT", "text_with_entity_marker": "The maximal insulin responses induced by [E1]OT[/E1] and AVP were very similar, but the threshold and maximal doses of AVP for increasing plasma insulin were higher than those of [E2]OT[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "OT", "entity_1_idx": [[41, 43]], "entity_1_idx_in_text_with_entity_marker": [45, 47], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "OT", "entity_2_idx": [[170, 172]], "entity_2_idx_in_text_with_entity_marker": [183, 185], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d56.s144_IEPA.d56.s144.p0", "text": "Surprisingly, however, when islets were depolarized directly using either of two agonists, glyburide (which does not act via generation of purine nucleotides) or 40 mM K+ (which acts distal to KATP channel), PLC and insulin secretion were again obliterated by IL-1 beta", "text_with_entity_marker": "Surprisingly, however, when islets were depolarized directly using either of two agonists, glyburide (which does not act via generation of purine nucleotides) or 40 mM K+ (which acts distal to KATP channel), [E1]PLC[/E1] and [E2]insulin[/E2] secretion were again obliterated by IL-1 beta", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PLC", "entity_1_idx": [[208, 211]], "entity_1_idx_in_text_with_entity_marker": [212, 215], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[216, 223]], "entity_2_idx_in_text_with_entity_marker": [229, 236], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d58.s153_IEPA.d58.s153.p4", "text": "We conclude that: (1) AVP causes a rapid, and reversible, phosphorylation of the MARCKS protein in the ovine anterior pituitary; (2) since the AVP-induced increase in MARCKS phosphorylation occurs much earlier in these cells than does PKC trans-location, MARCKS phosphorylation may provide a more sensitive index of the onset of PKC activation than the translocation assay; (3) the close temporal association between MARCKS phosphorylation and the rapid early release of ACTH suggests that MARCKS phosphorylation may be involved in the initial intracellular events that underly exocytosis of the hormone.", "text_with_entity_marker": "We conclude that: (1) AVP causes a rapid, and reversible, phosphorylation of the MARCKS protein in the ovine anterior pituitary; (2) since the [E1]AVP[/E1]-induced increase in MARCKS phosphorylation occurs much earlier in these cells than does PKC trans-location, MARCKS phosphorylation may provide a more sensitive index of the onset of [E2]PKC[/E2] activation than the translocation assay; (3) the close temporal association between MARCKS phosphorylation and the rapid early release of ACTH suggests that MARCKS phosphorylation may be involved in the initial intracellular events that underly exocytosis of the hormone.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "AVP", "entity_1_idx": [[143, 146]], "entity_1_idx_in_text_with_entity_marker": [147, 150], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "PKC", "entity_2_idx": [[329, 332]], "entity_2_idx_in_text_with_entity_marker": [342, 345], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d60.s156_IEPA.d60.s156.p0", "text": "We suggest that AVP activates the 42/44kDa MAPKs through a signal transduction pathway that involves stimulation of AVP-V1 receptor, tyrosine kinase, PKC and MEK", "text_with_entity_marker": "We suggest that [E1]AVP[/E1] activates the 42/44kDa MAPKs through a signal transduction pathway that involves stimulation of AVP-V1 receptor, tyrosine kinase, [E2]PKC[/E2] and MEK", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "AVP", "entity_1_idx": [[16, 19]], "entity_1_idx_in_text_with_entity_marker": [20, 23], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "PKC", "entity_2_idx": [[150, 153]], "entity_2_idx_in_text_with_entity_marker": [163, 166], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d65.s164_IEPA.d65.s164.p0", "text": "AVP induced a biphasic increase in diacylglycerol generation, characterized by an initial rapid rise and then a sustained elevation, and PKC activation, reflected by phosphorylation of a specific 80 kDa myristoylated alanine-rich PKC substrate (MARCKS)", "text_with_entity_marker": "[E1]AVP[/E1] induced a biphasic increase in diacylglycerol generation, characterized by an initial rapid rise and then a sustained elevation, and [E2]PKC[/E2] activation, reflected by phosphorylation of a specific 80 kDa myristoylated alanine-rich PKC substrate (MARCKS)", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "AVP", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "PKC", "entity_2_idx": [[137, 140]], "entity_2_idx_in_text_with_entity_marker": [150, 153], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d74.s177_IEPA.d74.s177.p0", "text": "In marked contrast, intracerebroventricular leptin administration was accompanied by the maintenance of high UCP1, UCP2, and UCP3 expression in all these tissues", "text_with_entity_marker": "In marked contrast, intracerebroventricular [E1]leptin[/E1] administration was accompanied by the maintenance of high [E2]UCP1[/E2], UCP2, and UCP3 expression in all these tissues", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "leptin", "entity_1_idx": [[44, 50]], "entity_1_idx_in_text_with_entity_marker": [48, 54], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP1", "entity_2_idx": [[109, 113]], "entity_2_idx_in_text_with_entity_marker": [122, 126], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d74.s177_IEPA.d74.s177.p1", "text": "In marked contrast, intracerebroventricular leptin administration was accompanied by the maintenance of high UCP1, UCP2, and UCP3 expression in all these tissues", "text_with_entity_marker": "In marked contrast, intracerebroventricular [E1]leptin[/E1] administration was accompanied by the maintenance of high UCP1, [E2]UCP2[/E2], and UCP3 expression in all these tissues", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "leptin", "entity_1_idx": [[44, 50]], "entity_1_idx_in_text_with_entity_marker": [48, 54], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP2", "entity_2_idx": [[115, 119]], "entity_2_idx_in_text_with_entity_marker": [128, 132], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d74.s177_IEPA.d74.s177.p3", "text": "In marked contrast, intracerebroventricular leptin administration was accompanied by the maintenance of high UCP1, UCP2, and UCP3 expression in all these tissues", "text_with_entity_marker": "In marked contrast, intracerebroventricular leptin administration was accompanied by the maintenance of high [E1]UCP1[/E1], [E2]UCP2[/E2], and UCP3 expression in all these tissues", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "UCP1", "entity_1_idx": [[109, 113]], "entity_1_idx_in_text_with_entity_marker": [113, 117], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP2", "entity_2_idx": [[115, 119]], "entity_2_idx_in_text_with_entity_marker": [128, 132], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d74.s178_IEPA.d74.s178.p5", "text": "While leptin maintains or favors energy-dissipating mechanisms (UCP1, UCP2, and UCP3), the latter are markedly depressed in pair-fed rats", "text_with_entity_marker": "While leptin maintains or favors energy-dissipating mechanisms (UCP1, [E1]UCP2[/E1], and [E2]UCP3[/E2]), the latter are markedly depressed in pair-fed rats", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "UCP2", "entity_1_idx": [[70, 74]], "entity_1_idx_in_text_with_entity_marker": [74, 78], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP3", "entity_2_idx": [[80, 84]], "entity_2_idx_in_text_with_entity_marker": [93, 97], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d77.s186_IEPA.d77.s186.p0", "text": "Three weeks after administration of STZ, the diabetic rats were subcutaneously treated with insulin for 1 week, which resulted in significant suppression of the induction of nNOS, AVP and oxytocin gene expression in the PVN and SON", "text_with_entity_marker": "Three weeks after administration of STZ, the diabetic rats were subcutaneously treated with [E1]insulin[/E1] for 1 week, which resulted in significant suppression of the induction of nNOS, AVP and [E2]oxytocin[/E2] gene expression in the PVN and SON", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "insulin", "entity_1_idx": [[92, 99]], "entity_1_idx_in_text_with_entity_marker": [96, 103], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "oxytocin", "entity_2_idx": [[188, 196]], "entity_2_idx_in_text_with_entity_marker": [201, 209], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d78.s188_IEPA.d78.s188.p2", "text": "These results confirm that AVP and PMA activate PKC and indicate that IL-1 likely does not activate PKC in Leydig cells", "text_with_entity_marker": "These results confirm that AVP and PMA activate [E1]PKC[/E1] and indicate that IL-1 likely does not activate [E2]PKC[/E2] in Leydig cells", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PKC", "entity_1_idx": [[48, 51]], "entity_1_idx_in_text_with_entity_marker": [52, 55], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "PKC", "entity_2_idx": [[100, 103]], "entity_2_idx_in_text_with_entity_marker": [113, 116], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d84.s199_IEPA.d84.s199.p0", "text": "Effect of residual endogenous insulin secretion on the abnormal oxytocin response to hypoglycaemia in insulin-dependent diabetics", "text_with_entity_marker": "Effect of residual endogenous [E1]insulin[/E1] secretion on the abnormal [E2]oxytocin[/E2] response to hypoglycaemia in insulin-dependent diabetics", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "insulin", "entity_1_idx": [[30, 37]], "entity_1_idx_in_text_with_entity_marker": [34, 41], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "oxytocin", "entity_2_idx": [[64, 72]], "entity_2_idx_in_text_with_entity_marker": [77, 85], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d85.s204_IEPA.d85.s204.p0", "text": "A barley gene encoding a novel DNA-binding protein (HRT) was identified by southwestern screening with baits containing a gibberellin phytohormone response element from an alpha-amylase promoter", "text_with_entity_marker": "A barley gene encoding a novel DNA-binding protein (HRT) was identified by southwestern screening with baits containing a [E1]gibberellin[/E1] phytohormone response element from an [E2]alpha-amylase[/E2] promoter", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "gibberellin", "entity_1_idx": [[122, 133]], "entity_1_idx_in_text_with_entity_marker": [126, 137], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "alpha-amylase", "entity_2_idx": [[172, 185]], "entity_2_idx_in_text_with_entity_marker": [185, 198], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d88.s207_IEPA.d88.s207.p4", "text": "To elucidate the pathophysiologic significance of UCP3 and UCP2 in the effect of TZDs on glucose metabolism and energy expenditure, we examined their basal mRNA levels in the WAT, brown adipose tissue (BAT), and skeletal muscle from Wistar fatty rats, a rat model of NIDDM and obesity with leptin receptor defect, and investigated expression of the genes encoding UCP3 and UCP2 in Wistar fatty rats and in Wistar lean rats with 2-week oral administration of 3 mg x kg(-1) x day(-1) pioglitazone, a TZD derivative", "text_with_entity_marker": "To elucidate the pathophysiologic significance of UCP3 and [E1]UCP2[/E1] in the effect of TZDs on glucose metabolism and energy expenditure, we examined their basal mRNA levels in the WAT, brown adipose tissue (BAT), and skeletal muscle from Wistar fatty rats, a rat model of NIDDM and obesity with [E2]leptin[/E2] receptor defect, and investigated expression of the genes encoding UCP3 and UCP2 in Wistar fatty rats and in Wistar lean rats with 2-week oral administration of 3 mg x kg(-1) x day(-1) pioglitazone, a TZD derivative", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "UCP2", "entity_1_idx": [[59, 63]], "entity_1_idx_in_text_with_entity_marker": [63, 67], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "leptin", "entity_2_idx": [[290, 296]], "entity_2_idx_in_text_with_entity_marker": [303, 309], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d89.s209_IEPA.d89.s209.p4", "text": "UCP2, UCP3 and leptin gene expression: modulation by food restriction and leptin", "text_with_entity_marker": "UCP2, [E1]UCP3[/E1] and leptin gene expression: modulation by food restriction and [E2]leptin[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "UCP3", "entity_1_idx": [[6, 10]], "entity_1_idx_in_text_with_entity_marker": [10, 14], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "leptin", "entity_2_idx": [[74, 80]], "entity_2_idx_in_text_with_entity_marker": [87, 93], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d89.s209_IEPA.d89.s209.p5", "text": "UCP2, UCP3 and leptin gene expression: modulation by food restriction and leptin", "text_with_entity_marker": "UCP2, UCP3 and [E1]leptin[/E1] gene expression: modulation by food restriction and [E2]leptin[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "leptin", "entity_1_idx": [[15, 21]], "entity_1_idx_in_text_with_entity_marker": [19, 25], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "leptin", "entity_2_idx": [[74, 80]], "entity_2_idx_in_text_with_entity_marker": [87, 93], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d89.s210_IEPA.d89.s210.p2", "text": "To determine the effects of food restriction and leptin administration on several transcripts involved in energy homeostasis, we examined leptin, uncoupling proteins (UCP) 1, 2 and 3, lipoprotein lipase (LPL), beta3-adrenergic receptors (beta3AR) and hormone-sensitive lipase (HSL) mRNA levels in brown adipose tissue (BAT) and epididymal (EWAT) and perirenal (PWAT) white adipose tissue in three groups of rats", "text_with_entity_marker": "To determine the effects of food restriction and leptin administration on several transcripts involved in energy homeostasis, we examined [E1]leptin[/E1], [E2]uncoupling proteins[/E2] (UCP) 1, 2 and 3, lipoprotein lipase (LPL), beta3-adrenergic receptors (beta3AR) and hormone-sensitive lipase (HSL) mRNA levels in brown adipose tissue (BAT) and epididymal (EWAT) and perirenal (PWAT) white adipose tissue in three groups of rats", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "leptin", "entity_1_idx": [[138, 144]], "entity_1_idx_in_text_with_entity_marker": [142, 148], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "uncoupling proteins", "entity_2_idx": [[146, 165]], "entity_2_idx_in_text_with_entity_marker": [159, 178], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d89.s211_IEPA.d89.s211.p5", "text": "Leptin increased LPL mRNA by 80%, UCP1 mRNA twofold, and UCP3 mRNA levels by 62% in BAT, and increased UCP2 mRNA levels twofold in EWAT", "text_with_entity_marker": "Leptin increased LPL mRNA by 80%, UCP1 mRNA twofold, and [E1]UCP3[/E1] mRNA levels by 62% in BAT, and increased [E2]UCP2[/E2] mRNA levels twofold in EWAT", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "UCP3", "entity_1_idx": [[57, 61]], "entity_1_idx_in_text_with_entity_marker": [61, 65], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP2", "entity_2_idx": [[103, 107]], "entity_2_idx_in_text_with_entity_marker": [116, 120], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d91.s218_IEPA.d91.s218.p2", "text": "U-73122 at 8 mumol.L-1 totally abolished the Oxy-induced increases in [Ca2+]i and IP3; however it reduced the Oxy-induced increase in insulin release only by 36% and 63% in the monolayer and suspended cell preparations, respectively", "text_with_entity_marker": "U-73122 at 8 mumol.L-1 totally abolished the Oxy-induced increases in [Ca2+]i and [E1]IP3[/E1]; however it reduced the [E2]Oxy[/E2]-induced increase in insulin release only by 36% and 63% in the monolayer and suspended cell preparations, respectively", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IP3", "entity_1_idx": [[82, 85]], "entity_1_idx_in_text_with_entity_marker": [86, 89], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "Oxy", "entity_2_idx": [[110, 113]], "entity_2_idx_in_text_with_entity_marker": [123, 126], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d91.s224_IEPA.d91.s224.p0", "text": "CONCLUSION: Oxy increases insulin release through both PLC and non-PLC mediated signal transduction mechanisms", "text_with_entity_marker": "CONCLUSION: [E1]Oxy[/E1] increases [E2]insulin[/E2] release through both PLC and non-PLC mediated signal transduction mechanisms", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Oxy", "entity_1_idx": [[12, 15]], "entity_1_idx_in_text_with_entity_marker": [16, 19], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[26, 33]], "entity_2_idx_in_text_with_entity_marker": [39, 46], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d93.s226_IEPA.d93.s226.p0", "text": "Further investigation suggested that activation of protein kinase C (PKC), which is part of the AVP-induced intracellular signalling pathway, is necessary and sufficient for the generation of the synergistic response, although it is not obligatory for AVP-induced ACTH release", "text_with_entity_marker": "Further investigation suggested that activation of [E1]protein kinase C[/E1] (PKC), which is part of the [E2]AVP[/E2]-induced intracellular signalling pathway, is necessary and sufficient for the generation of the synergistic response, although it is not obligatory for AVP-induced ACTH release", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "protein kinase C", "entity_1_idx": [[51, 67]], "entity_1_idx_in_text_with_entity_marker": [55, 71], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "AVP", "entity_2_idx": [[96, 99]], "entity_2_idx_in_text_with_entity_marker": [109, 112], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d93.s226_IEPA.d93.s226.p1", "text": "Further investigation suggested that activation of protein kinase C (PKC), which is part of the AVP-induced intracellular signalling pathway, is necessary and sufficient for the generation of the synergistic response, although it is not obligatory for AVP-induced ACTH release", "text_with_entity_marker": "Further investigation suggested that activation of [E1]protein kinase C[/E1] (PKC), which is part of the AVP-induced intracellular signalling pathway, is necessary and sufficient for the generation of the synergistic response, although it is not obligatory for [E2]AVP[/E2]-induced ACTH release", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "protein kinase C", "entity_1_idx": [[51, 67]], "entity_1_idx_in_text_with_entity_marker": [55, 71], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "AVP", "entity_2_idx": [[252, 255]], "entity_2_idx_in_text_with_entity_marker": [265, 268], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d96.s231_IEPA.d96.s231.p0", "text": "Downregulation of uncoupling protein 2 mRNA in white adipose tissue and uncoupling protein 3 mRNA in skeletal muscle during the early stages of leptin treatment", "text_with_entity_marker": "Downregulation of [E1]uncoupling protein 2[/E1] mRNA in white adipose tissue and [E2]uncoupling protein 3[/E2] mRNA in skeletal muscle during the early stages of leptin treatment", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "uncoupling protein 2", "entity_1_idx": [[18, 38]], "entity_1_idx_in_text_with_entity_marker": [22, 42], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "uncoupling protein 3", "entity_2_idx": [[72, 92]], "entity_2_idx_in_text_with_entity_marker": [85, 105], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d107.s247_IEPA.d107.s247.p0", "text": "Molecular characterization of catalytic-subunit cDNA sequences encoding protein phosphatases 1 and 2A and study of their roles in the gibberellin-dependent Osamy-c expression in rice", "text_with_entity_marker": "Molecular characterization of catalytic-subunit cDNA sequences encoding protein phosphatases 1 and 2A and study of their roles in the [E1]gibberellin[/E1]-dependent [E2]Osamy-c[/E2] expression in rice", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "gibberellin", "entity_1_idx": [[134, 145]], "entity_1_idx_in_text_with_entity_marker": [138, 149], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "Osamy-c", "entity_2_idx": [[156, 163]], "entity_2_idx_in_text_with_entity_marker": [169, 176], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d109.s259_IEPA.d109.s259.p2", "text": "Fasting significantly decreased BAT UCP-1 and UCP-3 mRNA expression, to 31% and 30% of ad libitum fed controls, respectively, effects which were prevented by administration of leptin to fasted rats", "text_with_entity_marker": "Fasting significantly decreased BAT UCP-1 and [E1]UCP-3[/E1] mRNA expression, to 31% and 30% of ad libitum fed controls, respectively, effects which were prevented by administration of [E2]leptin[/E2] to fasted rats", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "UCP-3", "entity_1_idx": [[46, 51]], "entity_1_idx_in_text_with_entity_marker": [50, 55], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "leptin", "entity_2_idx": [[176, 182]], "entity_2_idx_in_text_with_entity_marker": [189, 195], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d109.s261_IEPA.d109.s261.p4", "text": "Fasting, with or without leptin administration, did not affect BAT UCP-2 mRNA; however, leptin administration to ad libitum fed rats significantly increased BAT UCP-2 mRNA, to 138% of control", "text_with_entity_marker": "Fasting, with or without leptin administration, did not affect BAT [E1]UCP-2[/E1] mRNA; however, leptin administration to ad libitum fed rats significantly increased BAT [E2]UCP-2[/E2] mRNA, to 138% of control", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "UCP-2", "entity_1_idx": [[67, 72]], "entity_1_idx_in_text_with_entity_marker": [71, 76], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP-2", "entity_2_idx": [[161, 166]], "entity_2_idx_in_text_with_entity_marker": [174, 179], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d110.s266_IEPA.d110.s266.p1", "text": "Western blots demonstrated expression of PKCalpha, betaI, epsilon, delta, and zeta in H9c2 cells; PKC inhibitors (staurosporine or Ro 31-8220) or down-regulation of PKCalpha, betaI, epsilon, and delta by long-term (24 h) TPA treatment caused a partial blockade of the AVP-induced response, whereas the A23187-induced AA release was unaffected by down-regulation of these isoforms", "text_with_entity_marker": "Western blots demonstrated expression of PKCalpha, betaI, epsilon, delta, and zeta in H9c2 cells; [E1]PKC[/E1] inhibitors (staurosporine or Ro 31-8220) or down-regulation of PKCalpha, betaI, epsilon, and delta by long-term (24 h) TPA treatment caused a partial blockade of the [E2]AVP[/E2]-induced response, whereas the A23187-induced AA release was unaffected by down-regulation of these isoforms", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PKC", "entity_1_idx": [[98, 101]], "entity_1_idx_in_text_with_entity_marker": [102, 105], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "AVP", "entity_2_idx": [[268, 271]], "entity_2_idx_in_text_with_entity_marker": [281, 284], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d112.s271_IEPA.d112.s271.p0", "text": "Quantitative studies at early times demonstrated that cycloheximide treatment of aleurone layers increased mRNA levels 4-fold, whereas a combination of gibberellin plus cycloheximide treatment was required to increase alpha-amylase mRNA levels to the same extent", "text_with_entity_marker": "Quantitative studies at early times demonstrated that cycloheximide treatment of aleurone layers increased mRNA levels 4-fold, whereas a combination of [E1]gibberellin[/E1] plus cycloheximide treatment was required to increase [E2]alpha-amylase[/E2] mRNA levels to the same extent", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "gibberellin", "entity_1_idx": [[152, 163]], "entity_1_idx_in_text_with_entity_marker": [156, 167], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "alpha-amylase", "entity_2_idx": [[218, 231]], "entity_2_idx_in_text_with_entity_marker": [231, 244], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d113.s273_IEPA.d113.s273.p0", "text": "The low-performing Stock B animals were characterized by [1] being more reactive to sensory stimulation: higher startle amplitude and shorter startle latency; [2] having higher plasma insulin and corticosterone levels, whereas plasma gastrin and oxytocin were significantly lowered and a strong tendency for a decrease also in plasma CCK", "text_with_entity_marker": "The low-performing Stock B animals were characterized by [1] being more reactive to sensory stimulation: higher startle amplitude and shorter startle latency; [2] having higher plasma [E1]insulin[/E1] and corticosterone levels, whereas plasma gastrin and [E2]oxytocin[/E2] were significantly lowered and a strong tendency for a decrease also in plasma CCK", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin", "entity_1_idx": [[184, 191]], "entity_1_idx_in_text_with_entity_marker": [188, 195], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "oxytocin", "entity_2_idx": [[246, 254]], "entity_2_idx_in_text_with_entity_marker": [259, 267], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d117.s285_IEPA.d117.s285.p2", "text": "The second class of mutant, gse (GA sensitivity), differed principally in GA sensitivity, requiring approximately 100-fold higher [GA3] for both leaf elongation and alpha-amylase production by aleurone", "text_with_entity_marker": "The second class of mutant, gse ([E1]GA[/E1] sensitivity), differed principally in GA sensitivity, requiring approximately 100-fold higher [GA3] for both leaf elongation and [E2]alpha-amylase[/E2] production by aleurone", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GA", "entity_1_idx": [[33, 35]], "entity_1_idx_in_text_with_entity_marker": [37, 39], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "alpha-amylase", "entity_2_idx": [[165, 178]], "entity_2_idx_in_text_with_entity_marker": [178, 191], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d121.s289_IEPA.d121.s289.p0", "text": "An inhibitor of PKC, Ro31-8220 (10 microM), abolished the ability of PDBu to decrease [Ca(2+)](i), without affecting the response to maximal or submaximal concentrations of AVP", "text_with_entity_marker": "An inhibitor of [E1]PKC[/E1], Ro31-8220 (10 microM), abolished the ability of PDBu to decrease [Ca(2+)](i), without affecting the response to maximal or submaximal concentrations of [E2]AVP[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PKC", "entity_1_idx": [[16, 19]], "entity_1_idx_in_text_with_entity_marker": [20, 23], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "AVP", "entity_2_idx": [[173, 176]], "entity_2_idx_in_text_with_entity_marker": [186, 189], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d122.s294_IEPA.d122.s294.p0", "text": "Relative UCP expression levels were 100, 104, and 33 for UCP1, 100, 191, and 125 for UCP2 and 100, 107, and 29 for UCP3 in ad libitum fed control rats, in leptin-treated rats and in pair-fed control rats, respectively", "text_with_entity_marker": "Relative [E1]UCP[/E1] expression levels were 100, 104, and 33 for [E2]UCP1[/E2], 100, 191, and 125 for UCP2 and 100, 107, and 29 for UCP3 in ad libitum fed control rats, in leptin-treated rats and in pair-fed control rats, respectively", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "UCP", "entity_1_idx": [[9, 12]], "entity_1_idx_in_text_with_entity_marker": [13, 16], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP1", "entity_2_idx": [[57, 61]], "entity_2_idx_in_text_with_entity_marker": [70, 74], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d124.s297_IEPA.d124.s297.p0", "text": "By comparison with the promoters of alpha-amylase genes, which are also induced by GA, we suggest that GARE is coupled with the upstream element and the pyrimidine box to form a GA response complex", "text_with_entity_marker": "By comparison with the promoters of [E1]alpha-amylase[/E1] genes, which are also induced by [E2]GA[/E2], we suggest that GARE is coupled with the upstream element and the pyrimidine box to form a GA response complex", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "alpha-amylase", "entity_1_idx": [[36, 49]], "entity_1_idx_in_text_with_entity_marker": [40, 53], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "GA", "entity_2_idx": [[83, 85]], "entity_2_idx_in_text_with_entity_marker": [96, 98], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d126.s300_IEPA.d126.s300.p0", "text": "These results indicate that UCP gene expressions during pregnancy are regulated tissue-dependently, and up-regulation of uterine UCP2 and UCP3 mRNA may be due to increased leptin levels", "text_with_entity_marker": "These results indicate that [E1]UCP[/E1] gene expressions during pregnancy are regulated tissue-dependently, and up-regulation of uterine [E2]UCP2[/E2] and UCP3 mRNA may be due to increased leptin levels", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "UCP", "entity_1_idx": [[28, 31]], "entity_1_idx_in_text_with_entity_marker": [32, 35], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP2", "entity_2_idx": [[129, 133]], "entity_2_idx_in_text_with_entity_marker": [142, 146], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d127.s301_IEPA.d127.s301.p2", "text": "PI-PLC treatment of fetal guinea pig brain cultures substantially reduced the amount of Abeta40 and Abeta42 in the medium but had no effect on sAPPalpha", "text_with_entity_marker": "PI-PLC treatment of fetal guinea pig brain cultures substantially reduced the amount of [E1]Abeta40[/E1] and [E2]Abeta42[/E2] in the medium but had no effect on sAPPalpha", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Abeta40", "entity_1_idx": [[88, 95]], "entity_1_idx_in_text_with_entity_marker": [92, 99], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "Abeta42", "entity_2_idx": [[100, 107]], "entity_2_idx_in_text_with_entity_marker": [113, 120], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d127.s302_IEPA.d127.s302.p5", "text": "When this parental line was treated with PI-PLC, Abeta40, Abeta42, and sAPPbeta decreased to levels similar to those observed in the mutant line, and the mutant line was resistant to these effects of PI-PLC", "text_with_entity_marker": "When this parental line was treated with PI-PLC, Abeta40, [E1]Abeta42[/E1], and sAPPbeta decreased to levels similar to those observed in the mutant line, and the mutant line was resistant to these effects of [E2]PI-PLC[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Abeta42", "entity_1_idx": [[58, 65]], "entity_1_idx_in_text_with_entity_marker": [62, 69], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "PI-PLC", "entity_2_idx": [[200, 206]], "entity_2_idx_in_text_with_entity_marker": [213, 219], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d128.s303_IEPA.d128.s303.p0", "text": "A neurotoxic fragment of amyloid, Abeta 25-35, incubated in the presence of endogenous Ca2+, increased significantly the PI-PLC activity of normoxic brain", "text_with_entity_marker": "A neurotoxic fragment of [E1]amyloid[/E1], Abeta 25-35, incubated in the presence of endogenous Ca2+, increased significantly the [E2]PI-PLC[/E2] activity of normoxic brain", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "amyloid", "entity_1_idx": [[25, 32]], "entity_1_idx_in_text_with_entity_marker": [29, 36], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "PI-PLC", "entity_2_idx": [[121, 127]], "entity_2_idx_in_text_with_entity_marker": [134, 140], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d129.s309_IEPA.d129.s309.p1", "text": "We examined plasma leptin, leptin mRNA, and adipose and muscle UCP subtype mRNA in rats treated with alpha-methyl-p-tyrosine methyl ester (AMPT-ME), which inhibits catecholamine synthesis and 6-hydroxydopamine (6HDA), which is toxic to catecholinergic nerve terminals but, unlike AMPT-ME, does not enter the central nervous system", "text_with_entity_marker": "We examined plasma leptin, [E1]leptin[/E1] mRNA, and adipose and muscle [E2]UCP[/E2] subtype mRNA in rats treated with alpha-methyl-p-tyrosine methyl ester (AMPT-ME), which inhibits catecholamine synthesis and 6-hydroxydopamine (6HDA), which is toxic to catecholinergic nerve terminals but, unlike AMPT-ME, does not enter the central nervous system", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "leptin", "entity_1_idx": [[27, 33]], "entity_1_idx_in_text_with_entity_marker": [31, 37], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP", "entity_2_idx": [[63, 66]], "entity_2_idx_in_text_with_entity_marker": [76, 79], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d131.s317_IEPA.d131.s317.p0", "text": "The protein kinase C (PKC) inhibitors: staurosporine, H7 and GF109203X are able to block the AVP-stimulated phosphorylation", "text_with_entity_marker": "The [E1]protein kinase C[/E1] (PKC) inhibitors: staurosporine, H7 and GF109203X are able to block the [E2]AVP[/E2]-stimulated phosphorylation", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "protein kinase C", "entity_1_idx": [[4, 20]], "entity_1_idx_in_text_with_entity_marker": [8, 24], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "AVP", "entity_2_idx": [[93, 96]], "entity_2_idx_in_text_with_entity_marker": [106, 109], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d135.s323_IEPA.d135.s323.p0", "text": "These results suggest that, in isolated white adipocytes, the released adenosine acts as a helper and/or a positive regulator for insulin in the release of leptin via an activation of adenosine A1 receptors that involves the PLC-PKC pathway.", "text_with_entity_marker": "These results suggest that, in isolated white adipocytes, the released adenosine acts as a helper and/or a positive regulator for [E1]insulin[/E1] in the release of leptin via an activation of adenosine A1 receptors that involves the [E2]PLC[/E2]-PKC pathway.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "insulin", "entity_1_idx": [[130, 137]], "entity_1_idx_in_text_with_entity_marker": [134, 141], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "PLC", "entity_2_idx": [[225, 228]], "entity_2_idx_in_text_with_entity_marker": [238, 241], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d137.s326_IEPA.d137.s326.p0", "text": "Calphostin C and ET-18-OCH(3), inhibitors of protein kinase C, reduced the phosphorylation of p38 MAP kinase by AVP", "text_with_entity_marker": "Calphostin C and ET-18-OCH(3), inhibitors of [E1]protein kinase C[/E1], reduced the phosphorylation of p38 MAP kinase by [E2]AVP[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "protein kinase C", "entity_1_idx": [[45, 61]], "entity_1_idx_in_text_with_entity_marker": [49, 65], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "AVP", "entity_2_idx": [[112, 115]], "entity_2_idx_in_text_with_entity_marker": [125, 128], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d138.s332_IEPA.d138.s332.p2", "text": "The data suggest that mammalian insulin-sensitive cells and yeast share (part of) the key regulatory mechanism (consisting of PP2A, PKA, cAMP-PDE, and GPI-PLC) involved in the transduction of the insulin signal from the respective receptor systems to glycogen synthase and phosphorylase", "text_with_entity_marker": "The data suggest that mammalian insulin-sensitive cells and yeast share (part of) the key regulatory mechanism (consisting of PP2A, PKA, cAMP-PDE, and [E1]GPI-PLC[/E1]) involved in the transduction of the [E2]insulin[/E2] signal from the respective receptor systems to glycogen synthase and phosphorylase", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GPI-PLC", "entity_1_idx": [[151, 158]], "entity_1_idx_in_text_with_entity_marker": [155, 162], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[196, 203]], "entity_2_idx_in_text_with_entity_marker": [209, 216], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d145.s347_IEPA.d145.s347.p0", "text": "The effects of full-length amyloid beta protein, A(beta) (1-40), on phosphoinositide-specific phospholipase C (PLC) were investigated in synaptic plasma membranes (SPM) and cytosol prepared from the cerebral cortex of adult rats", "text_with_entity_marker": "The effects of full-length [E1]amyloid[/E1] beta protein, A(beta) (1-40), on phosphoinositide-specific [E2]phospholipase C[/E2] (PLC) were investigated in synaptic plasma membranes (SPM) and cytosol prepared from the cerebral cortex of adult rats", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "amyloid", "entity_1_idx": [[27, 34]], "entity_1_idx_in_text_with_entity_marker": [31, 38], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "phospholipase C", "entity_2_idx": [[94, 109]], "entity_2_idx_in_text_with_entity_marker": [107, 122], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d147.s358_IEPA.d147.s358.p2", "text": "With regard to CK2, phosphorylation occurs at Ser 154 with a stoichiometry of about 0.1 mol phosphate/mol rbPrP, which is doubled by mild heat treatment of rbPrP", "text_with_entity_marker": "With regard to CK2, phosphorylation occurs at Ser 154 with a stoichiometry of about 0.1 mol phosphate/mol [E1]rbPrP[/E1], which is doubled by mild heat treatment of [E2]rbPrP[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "rbPrP", "entity_1_idx": [[106, 111]], "entity_1_idx_in_text_with_entity_marker": [110, 115], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "rbPrP", "entity_2_idx": [[156, 161]], "entity_2_idx_in_text_with_entity_marker": [169, 174], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d151.s365_IEPA.d151.s365.p0", "text": "Relationship among leptin, neuropeptide Y, and galanin in young women and in postmenopausal women [see comments]", "text_with_entity_marker": "Relationship among [E1]leptin[/E1], [E2]neuropeptide Y[/E2], and galanin in young women and in postmenopausal women [see comments]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "leptin", "entity_1_idx": [[19, 25]], "entity_1_idx_in_text_with_entity_marker": [23, 29], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "neuropeptide Y", "entity_2_idx": [[27, 41]], "entity_2_idx_in_text_with_entity_marker": [40, 54], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d151.s367_IEPA.d151.s367.p1", "text": "CONCLUSIONS: Our results suggest that the differences is plasma leptin, NPY, and galanin between postmenopausal women and young women may be related to body mass index rather than to differences in hormonal status and that the higher NPY levels in both lean and obese postmenopausal women than in young women indicate that factors other than body mass index may be involved", "text_with_entity_marker": "CONCLUSIONS: Our results suggest that the differences is plasma [E1]leptin[/E1], NPY, and galanin between postmenopausal women and young women may be related to body mass index rather than to differences in hormonal status and that the higher [E2]NPY[/E2] levels in both lean and obese postmenopausal women than in young women indicate that factors other than body mass index may be involved", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "leptin", "entity_1_idx": [[64, 70]], "entity_1_idx_in_text_with_entity_marker": [68, 74], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "NPY", "entity_2_idx": [[234, 237]], "entity_2_idx_in_text_with_entity_marker": [247, 250], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d153.s369_IEPA.d153.s369.p0", "text": "Interestingly, both 5-HT and leptin modulate the action of NPY, which may form a part of a common output pathway for the expression of appetite", "text_with_entity_marker": "Interestingly, both 5-HT and [E1]leptin[/E1] modulate the action of [E2]NPY[/E2], which may form a part of a common output pathway for the expression of appetite", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "leptin", "entity_1_idx": [[29, 35]], "entity_1_idx_in_text_with_entity_marker": [33, 39], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "NPY", "entity_2_idx": [[59, 62]], "entity_2_idx_in_text_with_entity_marker": [72, 75], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d154.s371_IEPA.d154.s371.p2", "text": "Although X-Pro aminopeptidase (EC 3.4.11.9) is GPI-anchored in 3T3-L1 adipocytes as shown by digestion with bacterial phosphatidylinositol-specific phospholipase C, it was not released upon insulin treatment of the cells, indicating that only a subset of the GPI-anchored proteins are susceptible to insulin-stimulated release", "text_with_entity_marker": "Although X-Pro aminopeptidase (EC 3.4.11.9) is GPI-anchored in 3T3-L1 adipocytes as shown by digestion with bacterial phosphatidylinositol-specific phospholipase C, it was not released upon [E1]insulin[/E1] treatment of the cells, indicating that only a subset of the GPI-anchored proteins are susceptible to [E2]insulin[/E2]-stimulated release", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin", "entity_1_idx": [[190, 197]], "entity_1_idx_in_text_with_entity_marker": [194, 201], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[300, 307]], "entity_2_idx_in_text_with_entity_marker": [313, 320], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d159.s382_IEPA.d159.s382.p0", "text": "In the fasting state UCP-2 expression correlated inversely with body mass index (r = -0.45; P = 0.026), percent body fat (r = -0.41; P = 0.05), plasma insulin (r = -0.47; P = 0.02), epigastric venous fatty acids (r = -0.45; P = 0.04), and leptin (r = -0.50; P = 0.018)", "text_with_entity_marker": "In the fasting state [E1]UCP-2[/E1] expression correlated inversely with body mass index (r = -0.45; P = 0.026), percent body fat (r = -0.41; P = 0.05), plasma insulin (r = -0.47; P = 0.02), epigastric venous fatty acids (r = -0.45; P = 0.04), and [E2]leptin[/E2] (r = -0.50; P = 0.018)", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "UCP-2", "entity_1_idx": [[21, 26]], "entity_1_idx_in_text_with_entity_marker": [25, 30], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "leptin", "entity_2_idx": [[239, 245]], "entity_2_idx_in_text_with_entity_marker": [252, 258], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d161.s388_IEPA.d161.s388.p0", "text": "Marked increases in FAT/CD36 (724+/-18%; P < 0.05), PPAR-gamma2 (200+/-8%; P < 0.05), leptin (110+/-13%; P < 0.05), UCP-2 (120+/-7%; P < 0.05), UCP-3 (80+/-5%; P < 0.05), and TNF-alpha mRNA (130+/-12%; P < 0.05) were observed in comparison with pretreatment levels, whereas there was no change after saline infusion", "text_with_entity_marker": "Marked increases in FAT/CD36 (724+/-18%; P < 0.05), PPAR-gamma2 (200+/-8%; P < 0.05), [E1]leptin[/E1] (110+/-13%; P < 0.05), [E2]UCP-2[/E2] (120+/-7%; P < 0.05), UCP-3 (80+/-5%; P < 0.05), and TNF-alpha mRNA (130+/-12%; P < 0.05) were observed in comparison with pretreatment levels, whereas there was no change after saline infusion", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "leptin", "entity_1_idx": [[86, 92]], "entity_1_idx_in_text_with_entity_marker": [90, 96], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP-2", "entity_2_idx": [[116, 121]], "entity_2_idx_in_text_with_entity_marker": [129, 134], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d162.s390_IEPA.d162.s390.p0", "text": "We previously reported that adiposity and serum leptin levels increase with age in male F-344xBN rats and that when physiological levels of serum leptin are manipulated by fasting, there is a corresponding reciprocal change in hypothalamic neuropeptide Y (NPY) mRNA in young rats, but there are no changes in older rats", "text_with_entity_marker": "We previously reported that adiposity and serum [E1]leptin[/E1] levels increase with age in male F-344xBN rats and that when physiological levels of serum [E2]leptin[/E2] are manipulated by fasting, there is a corresponding reciprocal change in hypothalamic neuropeptide Y (NPY) mRNA in young rats, but there are no changes in older rats", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "leptin", "entity_1_idx": [[48, 54]], "entity_1_idx_in_text_with_entity_marker": [52, 58], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "leptin", "entity_2_idx": [[146, 152]], "entity_2_idx_in_text_with_entity_marker": [159, 165], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d162.s393_IEPA.d162.s393.p1", "text": "Leptin infusion diminished hypothalamic NPY levels by nearly 50% compared with pair-fed young rats, whereas there were no changes in the hypothalamic NPY mRNA levels in senescent rats", "text_with_entity_marker": "[E1]Leptin[/E1] infusion diminished hypothalamic NPY levels by nearly 50% compared with pair-fed young rats, whereas there were no changes in the hypothalamic [E2]NPY[/E2] mRNA levels in senescent rats", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Leptin", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "NPY", "entity_2_idx": [[150, 153]], "entity_2_idx_in_text_with_entity_marker": [163, 166], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d163.s395_IEPA.d163.s395.p0", "text": "C75 inhibited expression of the prophagic signal neuropeptide Y in the hypothalamus and acted in a leptin-independent manner that appears to be mediated by malonyl-coenzyme A", "text_with_entity_marker": "C75 inhibited expression of the prophagic signal [E1]neuropeptide Y[/E1] in the hypothalamus and acted in a [E2]leptin[/E2]-independent manner that appears to be mediated by malonyl-coenzyme A", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "neuropeptide Y", "entity_1_idx": [[49, 63]], "entity_1_idx_in_text_with_entity_marker": [53, 67], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "leptin", "entity_2_idx": [[99, 105]], "entity_2_idx_in_text_with_entity_marker": [112, 118], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d165.s401_IEPA.d165.s401.p0", "text": "Summing up, new evidence suggests that NPY and leptin may interact in a homeostatic loop to regulate body-fat mass and energy balance not only at the central nervous system level, but also directly at the adipocyte level", "text_with_entity_marker": "Summing up, new evidence suggests that [E1]NPY[/E1] and [E2]leptin[/E2] may interact in a homeostatic loop to regulate body-fat mass and energy balance not only at the central nervous system level, but also directly at the adipocyte level", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "NPY", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "leptin", "entity_2_idx": [[47, 53]], "entity_2_idx_in_text_with_entity_marker": [60, 66], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d168.s405_IEPA.d168.s405.p0", "text": "A reduction of food intake imposed on control rats (pair-feeding), aimed at mimicking leptin-induced hyperphagia, produced a marked decrease in the expression of muscle uncoupling protein-3 (UCP-3), whereas ICV infusion of leptin prevented such a decrease in UCP-3", "text_with_entity_marker": "A reduction of food intake imposed on control rats (pair-feeding), aimed at mimicking [E1]leptin[/E1]-induced hyperphagia, produced a marked decrease in the expression of muscle [E2]uncoupling protein-3[/E2] (UCP-3), whereas ICV infusion of leptin prevented such a decrease in UCP-3", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "leptin", "entity_1_idx": [[86, 92]], "entity_1_idx_in_text_with_entity_marker": [90, 96], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "uncoupling protein-3", "entity_2_idx": [[169, 189]], "entity_2_idx_in_text_with_entity_marker": [182, 202], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d168.s405_IEPA.d168.s405.p2", "text": "A reduction of food intake imposed on control rats (pair-feeding), aimed at mimicking leptin-induced hyperphagia, produced a marked decrease in the expression of muscle uncoupling protein-3 (UCP-3), whereas ICV infusion of leptin prevented such a decrease in UCP-3", "text_with_entity_marker": "A reduction of food intake imposed on control rats (pair-feeding), aimed at mimicking [E1]leptin[/E1]-induced hyperphagia, produced a marked decrease in the expression of muscle uncoupling protein-3 (UCP-3), whereas ICV infusion of leptin prevented such a decrease in [E2]UCP-3[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "leptin", "entity_1_idx": [[86, 92]], "entity_1_idx_in_text_with_entity_marker": [90, 96], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP-3", "entity_2_idx": [[259, 264]], "entity_2_idx_in_text_with_entity_marker": [272, 277], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d170.s412_IEPA.d170.s412.p0", "text": "Both leptin and insulin can reduce hypothalamic NPY production and secretion", "text_with_entity_marker": "Both [E1]leptin[/E1] and insulin can reduce hypothalamic [E2]NPY[/E2] production and secretion", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "leptin", "entity_1_idx": [[5, 11]], "entity_1_idx_in_text_with_entity_marker": [9, 15], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "NPY", "entity_2_idx": [[48, 51]], "entity_2_idx_in_text_with_entity_marker": [61, 64], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d174.s422_IEPA.d174.s422.p2", "text": "Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration", "text_with_entity_marker": "Dietary intakes of [E1]flavonols[/E1], flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL [E2]cholesterol[/E2] concentration", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "flavonols", "entity_1_idx": [[19, 28]], "entity_1_idx_in_text_with_entity_marker": [23, 32], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "cholesterol", "entity_2_idx": [[141, 152]], "entity_2_idx_in_text_with_entity_marker": [154, 165], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d179.s430_IEPA.d179.s430.p0", "text": "Recently several significant advances have been made in this area, including the identification of the appetite regulating hormone, leptin, and a detailed understanding of its targets in the central nervous system (CNS), such as neuropeptide Y (NPY) and the melanocortin-4 receptor", "text_with_entity_marker": "Recently several significant advances have been made in this area, including the identification of the appetite regulating hormone, [E1]leptin[/E1], and a detailed understanding of its targets in the central nervous system (CNS), such as [E2]neuropeptide Y[/E2] (NPY) and the melanocortin-4 receptor", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "leptin", "entity_1_idx": [[132, 138]], "entity_1_idx_in_text_with_entity_marker": [136, 142], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "neuropeptide Y", "entity_2_idx": [[229, 243]], "entity_2_idx_in_text_with_entity_marker": [242, 256], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d180.s432_IEPA.d180.s432.p0", "text": "When infused i.c.v. to normal rats to mimic its central effects, leptin decreases NPY levels, thus food intake and body weight", "text_with_entity_marker": "When infused i.c.v. to normal rats to mimic its central effects, [E1]leptin[/E1] decreases [E2]NPY[/E2] levels, thus food intake and body weight", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "leptin", "entity_1_idx": [[65, 71]], "entity_1_idx_in_text_with_entity_marker": [69, 75], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "NPY", "entity_2_idx": [[82, 85]], "entity_2_idx_in_text_with_entity_marker": [95, 98], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d199.s485_IEPA.d199.s485.p0", "text": "Our results indicate that glucose represses gibberellin signalling late along this hormone transduction pathway, downstream of transcription of the gibberellin-modulated transcriptional activator (GAMYB) needed for alpha-amylase induction", "text_with_entity_marker": "Our results indicate that glucose represses [E1]gibberellin[/E1] signalling late along this hormone transduction pathway, downstream of transcription of the [E2]gibberellin[/E2]-modulated transcriptional activator (GAMYB) needed for alpha-amylase induction", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gibberellin", "entity_1_idx": [[44, 55]], "entity_1_idx_in_text_with_entity_marker": [48, 59], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "gibberellin", "entity_2_idx": [[148, 159]], "entity_2_idx_in_text_with_entity_marker": [161, 172], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
